Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 485


Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.

Stockhausen MT, Kristoffersen K, Stobbe L, Poulsen HS.

Cancer Biol Ther. 2014 Feb;15(2):216-24. doi: 10.4161/cbt.26736. Epub 2013 Nov 1.


Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures.

Kristoffersen K, Villingshøj M, Poulsen HS, Stockhausen MT.

Cancer Biol Ther. 2013 Jul;14(7):625-37. doi: 10.4161/cbt.24595. Epub 2013 May 10.


Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature.

Kristoffersen K, Nedergaard MK, Villingshøj M, Borup R, Broholm H, Kjær A, Poulsen HS, Stockhausen MT.

Cancer Biol Ther. 2014 Jul;15(7):862-77. doi: 10.4161/cbt.28876. Epub 2014 Apr 22.


Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.

Stockhausen MT, Broholm H, Villingshøj M, Kirchhoff M, Gerdes T, Kristoffersen K, Kosteljanetz M, Spang-Thomsen M, Poulsen HS.

Exp Cell Res. 2011 Jul 1;317(11):1513-26. doi: 10.1016/j.yexcr.2011.04.001. Epub 2011 Apr 15.


Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.

Schulte A, Günther HS, Martens T, Zapf S, Riethdorf S, Wülfing C, Stoupiec M, Westphal M, Lamszus K.

Clin Cancer Res. 2012 Apr 1;18(7):1901-13. doi: 10.1158/1078-0432.CCR-11-3084. Epub 2012 Feb 7.


Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.

Eimer S, Dugay F, Airiau K, Avril T, Quillien V, Belaud-Rotureau MA, Belloc F.

Neuro Oncol. 2012 Dec;14(12):1441-51. doi: 10.1093/neuonc/nos266. Epub 2012 Oct 26.


The EGFRvIII variant in glioblastoma multiforme.

Gan HK, Kaye AH, Luwor RB.

J Clin Neurosci. 2009 Jun;16(6):748-54. doi: 10.1016/j.jocn.2008.12.005. Epub 2009 Mar 25. Review.


Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.

Bajetto A, Porcile C, Pattarozzi A, Scotti L, Aceto A, Daga A, Barbieri F, Florio T.

J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):143-54.


Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.

Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, Meling T, Murrell W, Vik Mo EO, Langmoen IA.

Oncotarget. 2015 Sep 22;6(28):26192-215. doi: 10.18632/oncotarget.4613.


Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.

Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A.

Cancer Res. 2009 Oct 1;69(19):7548-56. doi: 10.1158/0008-5472.CAN-08-4783. Epub 2009 Sep 22.


JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.

Zheng Q, Han L, Dong Y, Tian J, Huang W, Liu Z, Jia X, Jiang T, Zhang J, Li X, Kang C, Ren H.

Neuro Oncol. 2014 Sep;16(9):1229-43. doi: 10.1093/neuonc/nou046. Epub 2014 May 25.


Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.

Cancer Res. 2006 Jan 15;66(2):867-74.


Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Gilder AS, Jones KA, Hu J, Wang L, Chen CC, Carter BS, Gonias SL.

J Biol Chem. 2015 Jun 12;290(24):14798-809. doi: 10.1074/jbc.M115.637488. Epub 2015 Apr 2.


Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.

Friedman MD, Jeevan DS, Tobias M, Murali R, Jhanwar-Uniyal M.

Oncol Rep. 2013 Oct;30(4):1645-50. doi: 10.3892/or.2013.2625. Epub 2013 Jul 18.


The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.

Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR.

J Neurooncol. 2011 May;102(3):353-66. doi: 10.1007/s11060-010-0345-z. Epub 2010 Oct 12.


Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity.

Sun P, Xia S, Lal B, Shi X, Yang KS, Watkins PA, Laterra J.

BMC Cancer. 2014 Jun 4;14:401. doi: 10.1186/1471-2407-14-401.


Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.

Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S, Zorniak M, Wheeler DL, Kuo JS.

Neoplasia. 2012 May;14(5):420-8.


Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition.

Ying M, Wang S, Sang Y, Sun P, Lal B, Goodwin CR, Guerrero-Cazares H, Quinones-Hinojosa A, Laterra J, Xia S.

Oncogene. 2011 Aug 4;30(31):3454-67. doi: 10.1038/onc.2011.58. Epub 2011 Mar 7.


A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells.

Tate CM, Pallini R, Ricci-Vitiani L, Dowless M, Shiyanova T, D'Alessandris GQ, Morgante L, Giannetti S, Larocca LM, di Martino S, Rowlinson SW, De Maria R, Stancato L.

Cell Death Differ. 2012 Oct;19(10):1644-54. doi: 10.1038/cdd.2012.44. Epub 2012 Apr 27.

Supplemental Content

Support Center